JP3877961B2 - Ｃｎｓ疾患の治療におけるエピアロプレグナノロン - Google Patents

Ｃｎｓ疾患の治療におけるエピアロプレグナノロン Download PDF

Info

Publication number
JP3877961B2
JP3877961B2 JP2000535346A JP2000535346A JP3877961B2 JP 3877961 B2 JP3877961 B2 JP 3877961B2 JP 2000535346 A JP2000535346 A JP 2000535346A JP 2000535346 A JP2000535346 A JP 2000535346A JP 3877961 B2 JP3877961 B2 JP 3877961B2
Authority
JP
Japan
Prior art keywords
pregnan
hydroxy
treatment
steroid
epiallopregnanolone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000535346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002506034A (ja
JP2002506034A5 (https=
Inventor
ベクストルム，トルビエーン
ワン，ミン−デ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2002506034A publication Critical patent/JP2002506034A/ja
Publication of JP2002506034A5 publication Critical patent/JP2002506034A5/ja
Application granted granted Critical
Publication of JP3877961B2 publication Critical patent/JP3877961B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000535346A 1998-03-11 1999-03-10 Ｃｎｓ疾患の治療におけるエピアロプレグナノロン Expired - Fee Related JP3877961B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3786998A 1998-03-11 1998-03-11
US09/037,869 1998-03-11
PCT/EP1999/001496 WO1999045931A1 (en) 1998-03-11 1999-03-10 Epiallopregnanolone in the treatment of cns disorders

Publications (3)

Publication Number Publication Date
JP2002506034A JP2002506034A (ja) 2002-02-26
JP2002506034A5 JP2002506034A5 (https=) 2005-11-17
JP3877961B2 true JP3877961B2 (ja) 2007-02-07

Family

ID=21896803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000535346A Expired - Fee Related JP3877961B2 (ja) 1998-03-11 1999-03-10 Ｃｎｓ疾患の治療におけるエピアロプレグナノロン

Country Status (9)

Country Link
US (1) US6455516B1 (https=)
EP (1) EP1063999B1 (https=)
JP (1) JP3877961B2 (https=)
CN (1) CN1270718C (https=)
AT (1) ATE307592T1 (https=)
AU (1) AU756001B2 (https=)
CA (1) CA2321728C (https=)
DE (1) DE69927960T2 (https=)
WO (1) WO1999045931A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
CN101076340B (zh) * 2004-11-18 2011-01-12 梅克芳股份公司 Gaba-类固醇拮抗剂及其治疗cns障碍的用途
RU2413516C2 (ru) * 2004-11-18 2011-03-10 Умекрин Аб Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
DE102006003508A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Arzneimittel umfassend eine Hormonkombination
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
DK2792681T3 (en) 2006-11-21 2017-01-23 Umecrine Ab Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders.
US20100204192A1 (en) 2007-06-11 2010-08-12 University Of Sourthern California Agents, compositions and methods for enhancing neurological function
EP2167098B1 (en) * 2007-06-11 2018-09-05 University Of Southern California Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
RU2012133627A (ru) * 2010-01-14 2014-04-20 Умекрине Муд Аб Фармацевтическая композиция, содержащая 3-бета-гидрокси-5-альфа-прегнан-20-он, с улучшенными свойствами хранения и растворимости
PL2709631T3 (pl) 2011-05-20 2017-07-31 Inserm - Institut National De La Santé Et De La Recherche Médicale Antagoniści receptora cb1
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
EP2806877B2 (en) * 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
ES2621528T3 (es) 2012-11-28 2017-07-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Derivados de 3-(4’-sustituido)-bencil éter de pregnenolona
AU2013352141B2 (en) * 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
RU2684616C2 (ru) 2014-01-29 2019-04-10 Умекрин Когнишн Аб Стероидное соединение для применения в лечении печеночной энцефалопатии
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) * 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
KR20240157128A (ko) 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
RS67063B1 (sr) * 2017-01-09 2025-08-29 Relmada Therapeutics Inc Injektabilne suspenzije
WO2018147792A1 (en) * 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment
WO2018147791A1 (en) * 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
US20210228596A1 (en) * 2017-10-12 2021-07-29 Sage Therapeutics, Inc. Method of treating cns disorders with neurosteroids and gabaergic compounds
JP2021519799A (ja) 2018-04-05 2021-08-12 アサリナ ファーマ エーピーエス 物質離脱障害を治療するためのｇａｂａ−ａアンタゴニスト
KR20240050372A (ko) 2021-09-14 2024-04-18 난징 미노바 파마슈티컬 컴퍼니, 리미티드 수용성 알로프레그나놀론 유도체 및 이의 제조 방법과 용도
US20250387409A1 (en) 2021-11-10 2025-12-25 Umecrine Cognition Ab 3-beta-hydroxy-3-alpha-ethyl steroids for modulation of the alpha-3 subtype of the gabaa receptor
CA3237550A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
NZ298567A (en) * 1994-11-23 2000-01-28 Cocensys Inc Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment
BR9809376A (pt) * 1997-05-02 2000-07-04 American Home Prod Pregnan-3-ol-20-onas

Also Published As

Publication number Publication date
CA2321728A1 (en) 1999-09-16
EP1063999B1 (en) 2005-10-26
DE69927960D1 (de) 2005-12-01
CN1270718C (zh) 2006-08-23
CA2321728C (en) 2008-12-09
JP2002506034A (ja) 2002-02-26
DE69927960T2 (de) 2006-07-20
CN1300219A (zh) 2001-06-20
ATE307592T1 (de) 2005-11-15
AU3329299A (en) 1999-09-27
AU756001B2 (en) 2003-01-02
WO1999045931A1 (en) 1999-09-16
US6455516B1 (en) 2002-09-24
EP1063999A1 (en) 2001-01-03

Similar Documents

Publication Publication Date Title
JP3877961B2 (ja) Ｃｎｓ疾患の治療におけるエピアロプレグナノロン
AU2009201956B2 (en) Pregnane steroids for use in the treatment of CNS disorders
JP4152186B2 (ja) 減少された神経ステロイド活性に関連する疾患の治療でのｇａｂａエンハンサー
TW200829244A (en) Therapeutic combinations 482
WO2009142594A9 (en) The use of 3beta-ethenyl, methyl, 3alpha-hydroxy-steroids for the treatment of cns disorders
CA2218028C (en) Brain edema inhibitor
US20120142657A1 (en) Gaba-steroid antagonists and their use for the treatment of cns disorders
PT92799B (pt) Utilizacao de um agonista parcial de glicina b, nomeadamente um composto amino-isoxazolidina, para a preparacao de um medicamento empregue como antipsicotico e processo para a preparacao de uma composicao farmaceutica contendo o referido agonista
JP2002506822A (ja) ＧＡＢＡＡα５逆作動薬とニコチン作動薬との組合わせ
AU2020259269B2 (en) Treatment of migraine
JPH02209808A (ja) 物質嗜癖の治療法
WO2000007593A1 (en) Remedies or preventives for intractable epilepsy
WO2021159077A1 (en) Compositions and methods for attenuating opioid induced cardio and/or respiratory depression
US20220387407A1 (en) Compositions and methods for attenuating opioid induced cardio and/or respiratory depression
EA045860B1 (ru) АНТАГОНИСТЫ α2-АДРЕНОРЕЦЕПТОРОВ ПОДТИПА С (АЛЬФА-2С АДРЕНОРЕЦЕПТОРОВ) ДЛЯ ЛЕЧЕНИЯ АПНОЭ ВО СНЕ
JP2003527333A (ja) 低血圧およびショックの治療または予防
JPWO2000007593A1 (ja) 難治性てんかんの治療薬又は予防薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040408

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20060307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060621

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060922

TRDD Decision of grant or rejection written
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060922

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20061024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20061101

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091110

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091110

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101110

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101110

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111110

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121110

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131110

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees